Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q3 2023 call → NOWe need to determine if management explains where the company's business is going by narrating what its counterparties are themselves doing and scaling. The key is whether management's forward account is substantially about the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, etc., that the company already supplies, and that this is presented as the driver of the company's coming volume. Let's analyze the transcript. The call is about Quanterix, a life sciences company providing ultra-sensitive immunoassay technology (Simoa). They discuss their Q3 2023 results and outlook. Management (Masoud Toloue, CEO) talks about their transformation plan, gross margins, and then focuses on Alzheimer's disease biomarkers. They mention several partnerships and studies: - They mention a new agreement with Johnson & Johnson Innovative Medicines to launch a P-tau217 blood-based biomarker test. They describe the test's performance and the collaboration. - They mention Eli Lilly presented data at CTAD using Simoa platform for P-tau217. - They mention VUMC and Amsterdam studies. - They talk about the NIAAA guidelines. But the question is: does management explain where the company's business is going by narrating what its counterparties are themselves doing and scaling? That is, does management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, etc., such that the company's own coming volume is presented as a consequence of those parties' own trajectories? Let's look for evidence. Management talks about the J&J agreement: "we signed a new agreement with Johnson & Johnson Innovative Medicines and launched the Lucent AD P-tau217 blood based biomarker test... Our P-tau217 test achieved sensitivity, specificity, and an overall accuracy each exceeding 90%..." This is about a product launch, but does it describe J&J's own trajectory? It mentions the agreement and the test, but not J&J's scaling or ramp. It's more about the company's own product. They talk about Lilly's presentation: "Eli Lilly presented analytical validation and clinical performance of a P-tau217 blood based diagnostic test to identify amyloid PET positivity using the Simoa platform." This is about Lilly's study, but it's not about Lilly's own business scaling. It's about a study.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.